Ratings RaySearch Laboratories AB

Equities

RAY B

SE0000135485

Market Closed - Nasdaq Stockholm Other stock markets 11:29:44 2024-05-13 am EDT			5-day change	1st Jan Change
133.6 ^SEK	+0.75%		+8.44%	+47.95%

May. 06	C-RAD Partners with RaySearch Laboratories to Improve Radiation Therapy	MT
May. 04	RaySearch Laboratories AB and C-RAD Sign Collaboration Agreement	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company is in a robust financial situation considering its net cash and margin position.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 51.38 times its estimated earnings per share for the ongoing year.
With an enterprise value anticipated at 4.73 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
RAYSEARCH LABORATORIES AB	+47.95%	419M		C
VEEVA SYSTEMS INC.	+5.89%	32.93B		C
PRO MEDICUS LIMITED	+17.57%	7.94B		C-
SECTRA AB	+30.15%	4.19B		B-
EVOLENT HEALTH, INC.	-28.10%	2.8B		C-
OMNICELL, INC.	-18.15%	1.38B		B
LUNIT INC.	-33.33%	1.17B		-
SIMULATIONS PLUS, INC.	+9.61%	966M		C
B-SOFT CO.,LTD.	-37.56%	900M		-
VERADIGM INC.	-26.41%	839M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes